Efficacy and Safety of TQB2618 Injection Combined With Toripalimab Injection in Patients With Advanced Melanoma

Inclusion Criteria: * 1 Age: 18-75 years old;ECOG PS score: 0\~1;The expected survival is over 3 months * 2 Patients with advanced melanoma diagnosed histologically and/or cytologically * 3 At least one measurable lesion was confirmed according to RECIST 1.1 criteria * 4 Major organs are functioning normally * 5 Female subjects of reproductive age should agree to use contraceptive methods (such as intrauterine devices, birth control pills, or condoms) during the study period and for 6 months after the end of the study;Negative serum pregnancy/urine pregnancy test within 7 days prior to study enrollment and must be non-lactating subjects;Male subjects should agree to use contraception during the study and for six months after the end of the study period Exclusion Criteria: * 1 Present or present with other malignant tumors within 3 years prior to first use * 2 Unalleviated toxicity above CTCAE grade 1 due to any prior treatment * 3 Major surgical treatment and significant traumatic injury were performed within 28 days prior to initial administration * 4 A wound or fracture that has not healed for a long time * 5 Those who have a history of psychotropic drug abuse and can't get rid of it or have mental disorders * 6 Subject with any severe and/or uncontrolled disease * 7 Prior chemotherapy within 3 weeks prior to initial drug use, and prior radiotherapy or other antineoplastic drugs within 2 weeks prior to initial drug use * 8 Those who have participated in and used other antitumor clinical trials within 4 weeks prior to the first drug use